Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation.

Johns Hopkins, Baltimore, Maryland, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Baltimore, Maryland
Treatments:Chemotherapy, RadiationHospital:Johns Hopkins
Drugs:Journal:Link
Date:Jul 2002

Description:

Patients: This Phase II study involved 50 newly diagnosed glioblastoma multiforme patients.

Treatment: Treatment consisted of RSR13 (efaproxiral) and standard cranial radiotherapy. RSR13 is a synthetic allosteric modifier of hemoglobin, a radiation-enhancing agent.

Toxicity: One patient died of adult respiratory distress syndrome. A causative or contributory role of RSR13 in this fatal reaction could not be excluded. Twenty-four percent of patients experienced grade 3 or greater RSR13-related toxicity which included: nausea (grade 3), headache (grade 3), allergic rash (grade 3), hypotension (grade 3), transient creatinine increase (grades 2 and 4), and sepsis (grades 3 and 4).

Results: Survival was assessed from the date of histologic diagnosis. Median survival was 12.3 months.

Support: This study was supported in part by Allos Therapeutics. This company markets RSR13 (a.k.a. Efaproxyn (Efaproxiral)).

Correspondence: Lawrence Kleinberg, MD




Back